Fewer ads cause WebMD to revise outlook

Share this article:
Shares of WebMD parent company WebMD Health Corp dipped 12% yesterday after the company revised its outlook due to a lack of healthcare advertisers spending money with the firm. 

Shares fell $3.57, or 12.3%, to $25.46 in afternoon trading, the Associated Press reported. 

WebMD now expects net income for the year between $29.5 million and $37.5 million down from prior estimates for profit of $36.5 million to $46 million.

The AP reported that Citigroup analyst Mark Mahaney lowered his outlook on WebMD for 2008. He reiterated a "hold" rating on the stock.

Goldman Sachs analyst Jennifer Watson said the degree of the company's outlook revision and its explanation that drugmakers are hesitant to commit to advertising spending six to 12 months in advance, were surprising. 

“The biggest question is whether the slower trends are WebMD-specific or industry-wide," Watson wrote in a note to clients. “Specifically, we wonder if advertisers are testing lower-cost options, including emerging ad networks that deliver impressions across smaller consumer health and beauty sites.”
Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.